Shaperon, a South Korea-based biopharmaceutical company specialising in immune therapeutics, has signed a Memorandum of Understanding (MoU) with Dong-A ST for the development of nanobody-based new drugs.
Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development
Shaperon & Hudson to Participate in the 2024 Bio International Convention
Shaperon to Conduct Strategic Partnering and Institutional Investor Meetings at the 10th Annual BFC Healthcare Business Development & Investment Conference in Shanghai
CAMBRIDGE, Mass. & SEOUL, South Korea--(BUSINESS WIRE)--Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon’s effort to advance treatment for patients globally.